A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

Overview

The main purpose of this study is to investigate Lu AG06466 as a treatment for spasticity in participants with multiple sclerosis (MS).

Full Title of Study: “Interventional, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1B Study Investigating the Effects of Lu AG06466 for the Treatment of Spasticity in Patients With Multiple Sclerosis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 19, 2023

Detailed Description

The participants will be randomized to Lu AG06466 or placebo in a 2:1 ratio.

Interventions

  • Drug: Lu AG06466
    • Lu AG06466 – capsule
  • Drug: Placebo
    • Placebo – capsule

Arms, Groups and Cohorts

  • Experimental: Lu AG06466
    • Participants will receive Lu AG06466 at a starting dose orally once daily for 4 days (Day 1 to Day 4), followed by Lu AG06466 at a higher titrated dose orally once daily for 4 days (Day 5 to Day 8), followed by Lu AG06466 at a higher titrated treatment dose orally once daily from Day 9 until Day 35/Week 5.
  • Placebo Comparator: Placebo
    • Participants will receive Lu AG06466-matching placebo orally once daily until Day 35/Week 5.

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants with Spasticity Response
    • Time Frame: Baseline to Week 5
    • Spasticity response defined as ≥30% increase from baseline in spasticity Numerical Rating Scale (NRS) score
  • Change from Baseline to Week 5 in Spasticity NRS Score
    • Time Frame: Baseline, Week 5

Participating in This Clinical Trial

Key Inclusion Criteria:

  • The participant has a diagnosis of MS, as per the 2017 McDonald criteria. – The participant has clinically stable MS (such as no relapse and/or stable Expanded Disability Status Scale [EDSS] or alternative clinical assessment score) for at least 6 months prior to screening. – The participant has ongoing spasticity for at least 90 days prior to screening. – The participant is on a stable regimen for at least 30 days prior to screening for all medications and non pharmacological therapies, including therapies that are intended to alleviate spasticity (for example, oral baclofen, tizanidine, dalfampridine), and willing to remain on the same regimen throughout the duration of the study. – The participant reports walking impairment due to lower limb spasticity. Key Exclusion Criteria:

  • The participant has any concomitant disease or disorder that has spasticity-like symptoms or that may influence the participant's level of spasticity or the participant's overall ability to participate in the study. – The participant has ambulation difficulties due to any concomitant disease or disorder other than MS. – The participant has any known or suspected hypersensitivity to cannabinoids (CBs) or any of the excipients of the investigational medicinal product (IMP). – The participant has a positive drug screening test, except for non-CB medications used to treat a medical condition and reported as such by the participant; the participant has a positive drug screen test for cannabis/delta-9-tetrahydrocannabinol. Other inclusion and exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • H. Lundbeck A/S
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Email contact via H. Lundbeck A/S, Study Director, LundbeckClinicalTrials@Lundbeck.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.